Timing of Thyroxine Dose In Ramadan

NCT ID: NCT05421468

Last Updated: 2022-06-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-14

Study Completion Date

2022-10-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Randomized trial comparing two different timing of taking thyroxine in patients with Hypothyroidism during fasting the month of Ramadan.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To date there is debate regarding the best timing of L-thyroxine administration during Ramadan as sufficient evidence is lacking. This study aims to compare two-time points of levothyroxine intake during Ramadan focusing on change in TSH, satisfaction and compliance.

A prospective, randomized, open label, multicenter Study. The first group will be will be instructed to take their L-thyroxin dose as per current guidlines at breaking of fast time (sunset) with sip of water then wait 30-60 minutes to consume Iftar meal. The second group (pre-Fajer prayer), patients are going to be instructed to take L-thyroxin dose immediately before start of fast, i.e. Alfajer (dawn) regardless of Suhoor time. The values of Thyroid stimulating hormone (TSH) will be measured two weeks before Ramadan, and 2-4 weeks after Ramadan for comparison.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypothyroidism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pre-Iftar (Breaking the fast)

To take thyroxine at breaking of fast with sip of water then wait 30-60 miuntes to eat iftar (breakfast).

Group Type ACTIVE_COMPARATOR

L-Thyroxine time B (5-15 minutes Before dawn)

Intervention Type OTHER

Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.

Pre-Fajr (Starting the fast)

To take thyroxine immediately before start of fast at predawn time regardless of last meal time.

Group Type EXPERIMENTAL

L-Thyroxine time B (5-15 minutes Before dawn)

Intervention Type OTHER

Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

L-Thyroxine time B (5-15 minutes Before dawn)

Taking thyroxine at two different time points in relation to fasting and food intake; just before dawn and start of fast compared to the usual timing of 30-60minutes after the sunset breakfast meal.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Saudi patient (males and female) above 18 years with Primary hypothyroidism on levothyroxine replacement who are willing to fast during Ramadan.
* Patients with controlled thyroid function for last 3 months on same dose of levothyroxine.

Exclusion Criteria

* Pregnant or lactating women.
* Uncontrolled thyroid function test three months prior Ramadan.
* Thyroid cancer patients who require suppressed TSH.
* Central Hypothyroidism, patient with acute illness.
* Patients diagnosed with malabsorption i.e., Celiac Disease, Short bowel, Bariatric surgeries

* Use of certain Medications like systemic glucocorticoids, activated charcoal, sucralfate, aluminum hydroxide antacid, bile acid sequestrants, iron, calcium carbonate, PPI, rifampicin, and antiepileptic medications
* Renal or hepatic disease:
* Creatinine clearance \<0.6 ml/s or serum creatinine ≥200 μmol/l
* Alanine transferase ≥2.5 times the upper limit of normal
* Active liver disease including jaundice, chronic hepatitis, previous liver transplant
* Unwillingness to be randomized or to sign informed consent
* Known Psychiatric Disorders
* Known uncontrolled substance abuse or alcoholism
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

King Abdullah International Medical Research Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Reem Alamoudi

Jeddah, , Saudi Arabia

Site Status RECRUITING

KingAbullahIMRC

Jeddah, , Saudi Arabia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Saudi Arabia

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Reem Alamoudi

Role: primary

0122266666

Reem M Alamoudi

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ICT22J-001-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Iodine Supplementation in Graves' Hyperthyroidism
NCT06540469 NOT_YET_RECRUITING NA
Early Levothyroxine Post Radioactive Iodine
NCT01950260 COMPLETED PHASE2/PHASE3
Thyroxine Titration Study
NCT00111735 UNKNOWN PHASE4